MapLight Therapeutics (MPLT) Accumulated Depreciation (2024 - 2025)
MapLight Therapeutics recorded quarterly Accumulated Depreciation of $2.6 million in Q4 2025, up 5.56% quarter-over-quarter from $2.5 million in Q3 2025, and up 26.75% year-over-year from $2.1 million in Q4 2024.
MapLight Therapeutics' Accumulated Depreciation history runs 2 years deep, the most recent figure standing at $2.6 million for Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 26.75% year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $2.6 million (up 26.75% YoY), while the FY2025 annual figure was $2.6 million, up 26.75% from the prior year.
- Accumulated Depreciation came in at $2.6 million for Q4 2025 at MapLight Therapeutics, up from $2.5 million in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $2.6 million in Q4 2025 to a low of $2.1 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.64 Mn |
| Sep 30, 2025 | 2.50 Mn |
| Dec 31, 2024 | 2.08 Mn |